# Wolverine Legal Status: BPC-157 TB-500 FDA 503A Category & Compounding Access

> Wolverine legal status: neither BPC-157 nor TB-500 is FDA-approved, and the BPC-157 TB-500 blend's components are FDA 503A Category 2 bulk substances since the Sept 29, 2023 update. The compounding-access pathway, the July 2026 PCAC review, and WADA status — cited to FDA.

Present-tense facts only: both components are FDA 503A Category 2, compounding is restricted, and the status is under active FDA review ahead of a scheduled July 2026 advisory meeting. General information, not advice.

## Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status starts from one fact: neither component is an FDA-approved drug, and the blend has no approved indication. Both BPC-157 and the TB-500 fragment of Thymosin Beta-4 are, as of this writing, FDA 503A Category 2 bulk drug substances — a present-tense status, and the anchor for everything on this page [9]. Category 2 means the FDA identified each as a bulk drug substance that may present significant safety risks; pharmacy compounding under Section 503A is restricted, and the substances are not covered by the enforcement-discretion policy that applies to Category 1 [9][10].

That status is under active FDA review and could change. Both BPC-157 and TB-500 are on the published agenda of the Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, listed as substances 'being considered for inclusion on the 503A Bulks List' [11]. That is a scheduled discussion of substances under evaluation — not a decision, not a reclassification, and not dated as any outcome. Access could expand following that review, or it could not; nothing on this page should be read as predicting either. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.

## What FDA 503A Category 2 means, and how it became the status

Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered 'outsourcing facilities' that compound larger batches under cGMP-style oversight [10]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated through a public nomination process with input from the Pharmacy Compounding Advisory Committee [10].

Per the FDA's interim policy, Category 1 substances may be eligible for the 503A bulks list and are covered by enforcement discretion while under evaluation; Category 2 substances are those the FDA identified as raising significant safety risks and are not afforded that discretion — the FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [10]. BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' were each placed in Category 2 effective with the FDA's September 29, 2023 update to the list of nominated bulk substances, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [9]. The FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 [9].

## The general access pathway for a lawfully compounded medication

Where a substance is eligible for compounding, U.S. access follows one general pathway, described here in non-specific terms and naming no provider. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [10]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [10].

Telehealth is one front-end channel for the prescriber-evaluation step — a route to a licensed-prescriber consultation and prescription, not a separate legal status. It does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [10]. And it carries one decisive caveat: the compounder may use a requested ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. While BPC-157 and the TB-500 fragment stand in Category 2, they are flagged for significant safety risks and are not eligible for routine 503A compounding [9][10]. This page does not describe any way to obtain a restricted substance outside that framework.

## Regulatory and safety FAQ

### Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither component is FDA-approved for human use and the blend has no approved indication. Both BPC-157 and the TB-500 fragment of Thymosin Beta-4 are FDA 503A Category 2 bulk substances, restricting pharmacy compounding pending evaluation [9][10]. Both are also prohibited in sport by the World Anti-Doping Agency.

### Is the Wolverine blend legal?
Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved indication; both are FDA 503A Category 2 substances, so pharmacy compounding under 503A is restricted pending the FDA's ongoing evaluation [9][10][11]. Both are WADA-prohibited in sport. Material sold outside that framework is unregulated, with unverified identity and purity.

### Can you get BPC-157 from a compounding pharmacy?
BPC-157 is an FDA 503A Category 2 bulk substance — the FDA identified it as potentially presenting significant safety risks and it is not within the enforcement-discretion policy for 503A compounding [9][10]. It is on the July 23-24, 2026 PCAC agenda as a substance under evaluation for the 503A bulks list, which is a scheduled discussion, not a listing [11].

### What is the FDA 503A status of Wolverine?
The blend is not an approved drug. Both of its components — BPC-157 and the TB-500 fragment of Thymosin Beta-4 — are FDA 503A Category 2 bulk substances as of the September 29, 2023 update, excluded from routine compounding pending review, and both are on the scheduled July 2026 PCAC agenda for evaluation (a discussion, not a decision) [9][11].

### What are the side effects of BPC-157 and TB-500?
There are no controlled human safety data for the blend [6][7]. A key theoretical concern is the pro-angiogenic and pro-migratory profile of Thymosin Beta-4, which is implicated in tumor metastasis and angiogenesis [4]; BPC-157's long-term human safety is unknown [8]. Reviews treat both as investigational.

### Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is overexpressed in several cancers and has been implicated in metastasis and tumor angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a theoretical safety signal, not a demonstrated effect of the blend in humans.

---

A barely-there evidence ledger of the BPC-157 and TB-500 record — the few single-compound findings that hold set in one tier, the blend-level and access gaps left one tier down and in plain sight, with no clinic behind the page and nothing here dispensed.